
Opinion|Podcasts|March 13, 2024
Widening the Therapeutic Window in the Management of Parkinson’s Disease
Listen
0:00 / 0:00
Expert neurologists discuss strategies to widen the therapeutic window of Parkinson’s disease and options available to treat dyskinesia, providing better control of Parkinson’s disease.
Advertisement
1:12 Long-term challenges
4:00 Levodopa fluctuations
6:30 Therapeutic window
9:20 Amantadine DR/ER for PD
11:30 Dyskinesia treatment
18:10 Amantadine candidates
23:34 PK of amantadine
27:15 Early treatment
Advertisement
Latest CME
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Roche Unveils PrevenTRON, a Phase 3 Prevention Trial of Trontinemab in Cognitively Unimpaired Individuals at High Risk of Alzheimer Decline
2
Sanofi's Oral TREM2 Agonist SAR448851 Advances to Phase 2 TREMHANCE Trial in Early Alzheimer Disease
3
Alzheimer's Association Launches PROTECT-Cog Combination Prevention Trial
4
This Week on NeurologyLive® — July 20, 2026
5

















